CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $73.93 Average Target Price from Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has earned an average recommendation of "Hold" from the seventeen research firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $73.93.

A number of research analysts recently issued reports on CRSP shares. Chardan Capital increased their price objective on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a "buy" rating in a report on Thursday, February 22nd. Morgan Stanley increased their price objective on CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an "underweight" rating in a report on Monday, February 26th. Wells Fargo & Company decreased their price objective on CRISPR Therapeutics from $70.00 to $65.00 and set an "equal weight" rating for the company in a report on Thursday, May 9th. Wolfe Research began coverage on CRISPR Therapeutics in a research report on Thursday, February 15th. They set a "peer perform" rating for the company. Finally, JMP Securities reissued a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, May 9th.

Insider Activity

In other news, CEO Samarth Kulkarni sold 20,000 shares of the firm's stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $72.48, for a total value of $1,449,600.00. Following the completion of the sale, the chief executive officer now directly owns 208,122 shares of the company's stock, valued at $15,084,682.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Raju Prasad sold 3,524 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $72.69, for a total transaction of $256,159.56. Following the completion of the sale, the chief financial officer now directly owns 6,476 shares of the company's stock, valued at approximately $470,740.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $72.48, for a total value of $1,449,600.00. Following the sale, the chief executive officer now directly owns 208,122 shares of the company's stock, valued at $15,084,682.56. The disclosure for this sale can be found here. Insiders sold a total of 63,992 shares of company stock valued at $4,525,135 over the last three months. Insiders own 4.10% of the company's stock.

Institutional Trading of CRISPR Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Jump Financial LLC lifted its holdings in CRISPR Therapeutics by 194.7% during the 3rd quarter. Jump Financial LLC now owns 33,307 shares of the company's stock worth $1,512,000 after purchasing an additional 22,006 shares during the last quarter. Invesco Ltd. increased its stake in CRISPR Therapeutics by 1.5% during the 3rd quarter. Invesco Ltd. now owns 136,123 shares of the company's stock worth $6,179,000 after acquiring an additional 2,061 shares during the period. ARK Investment Management LLC increased its stake in CRISPR Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company's stock worth $534,360,000 after acquiring an additional 1,372,986 shares during the period. Prime Capital Investment Advisors LLC bought a new position in CRISPR Therapeutics during the 4th quarter worth $206,000. Finally, Baker Chad R increased its stake in CRISPR Therapeutics by 89.1% during the 4th quarter. Baker Chad R now owns 98,520 shares of the company's stock worth $6,167,000 after acquiring an additional 46,420 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock traded up $0.55 during trading hours on Friday, hitting $56.22. The company's stock had a trading volume of 1,071,541 shares, compared to its average volume of 1,749,516. The company has a market capitalization of $4.77 billion, a PE ratio of -20.67 and a beta of 1.80. CRISPR Therapeutics has a 12 month low of $37.55 and a 12 month high of $91.10. The stock has a 50 day moving average of $62.56 and a 200 day moving average of $65.09.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.08). The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. The business's quarterly revenue was down 99.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.67) EPS. Equities analysts expect that CRISPR Therapeutics will post -5.64 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.